SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-013233
Filing Date
2020-11-09
Accepted
2020-11-09 06:17:59
Documents
59
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20200930x10q.htm   iXBRL 10-Q 2151407
2 EX-10.1 tbph-20200930xex10d1.htm EX-10.1 19027
3 EX-31.1 tbph-20200930xex31d1.htm EX-31.1 13465
4 EX-31.2 tbph-20200930xex31d2.htm EX-31.2 14254
5 EX-32.1 tbph-20200930xex32d1.htm EX-32.1 15680
6 GRAPHIC tbph-20200930xex10d1001.jpg GRAPHIC 4709
  Complete submission text file 0001558370-20-013233.txt   7049163

Data Files

Seq Description Document Type Size
7 EX-101.SCH tbph-20200930.xsd EX-101.SCH 41839
8 EX-101.CAL tbph-20200930_cal.xml EX-101.CAL 53637
9 EX-101.DEF tbph-20200930_def.xml EX-101.DEF 148795
10 EX-101.LAB tbph-20200930_lab.xml EX-101.LAB 390103
11 EX-101.PRE tbph-20200930_pre.xml EX-101.PRE 290080
12 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20200930x10q_htm.xml XML 1184370
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 201296001
SIC: 2834 Pharmaceutical Preparations